Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02031497
Other study ID # 2012EL0905SEDULC
Secondary ID 120901-10
Status Completed
Phase N/A
First received January 8, 2014
Last updated March 2, 2017
Start date October 2012
Est. completion date December 2014

Study information

Verified date March 2017
Source Institute For European Expertise in Physiology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether consumption of carbonated drinks containing sweeteners affect insulin sensitivity.


Description:

Sweeteners are natural or synthetic sugar substitutes which provide a sweetness taste to drink and food with few or no additional calories. Sweeteners are widely used in commercialized beverages. Despite some debate, no significant toxicity was demonstrated at a reasonable level of consumption (less than 20 cans per day). However little data is available on the metabolic effects of a regular consumption of beverages containing sweeteners. The objective of the study is to evaluate the effect of a regular consumption (twice a day for 12 weeks) of a carbonated drink with sweeteners, in a normal diet, compared with unsweetened sparkling water on insulin sensitivity in healthy normoweight and overweight subjects.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 2014
Est. primary completion date April 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Healthy male or female

- Subject taking at least three main meals (breakfast, lunch, dinner)

- Subject able to understand and sign an informed consent

- Subject drinking and enjoying soft drinks

- Subject appreciating sweeteners taste

- 19 kg/m² < BMI< 30 kg/m²

Exclusion Criteria:

- Any severe or acute illness that may influence the results of the study or may be life-threatening

- Pregnant or breastfeeding subject

- Past or present metabolic or digestive diseases, with the exception of a possible appendectomy

- Diabetes or severe acute illness that may alter blood sugar

- Treatment that may interfere with glucose homeostasis

- Past or present kidney disease (renal failure, ... )

- Local or systemic medication that may change water status, metabolism and feeding behavior

- Antiplatelet treatment

- Alcohol consumption = 3-4 glasses / day ( = 21 drinks / week )

- Sustained physical exercise (more than 4 hours per week)

- Subject adding sweeteners (tablets or powder) in their diet

- Subject drinking more than two cans of drinks with sweeteners / day

- Subject dieting to lose weight

- Subject unable or unwilling to consume 2 liters of fluid / day

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Drink with sweeteners
Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.
Drink without sweeteners
Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.

Locations

Country Name City State
France Unit of Clinical Investigation,Centre Hospitalo-Universitaire de Rennes Rennes

Sponsors (1)

Lead Sponsor Collaborator
Institute For European Expertise in Physiology

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Matsuda Insulin sensitivity Index Before and after each of the two 12-week intervention period
Secondary Insulinogenic Index defined as ? insulin 0-30 / ? glucose 0-30 Before and after each of the two 12-week intervention period
Secondary Disposition index defined as Insulin sensitivity x insulinogenic Index Before and after each of the two 12-week intervention period
Secondary HOMA-IR Index defined as fasting Glycemia x fasting insulinemia/22.5 Before and after each of the two 12-week intervention period
Secondary Dietary intake Before and after each of the two 12-week intervention period
Secondary Physical activity Before and after each of the two 12-week intervention period
See also
  Status Clinical Trial Phase
Completed NCT01143493 - The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease
Withdrawn NCT01573806 - Pharmacology of Exenatide in Pediatric Sepsis Phase 1/Phase 2
Active, not recruiting NCT00947011 - Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1) Phase 2
Completed NCT00822003 - Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile in Healthy Male Subjects Phase 1/Phase 2
Completed NCT02237079 - Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM) Phase 4